SK Biopharmaceuticals broadened its U.S. prospects by licensing Biohaven’s global rights (outside its retained territories) to opakalim, a Kv7-targeting small molecule in pivotal testing for epilepsy. The arrangement includes non-dilutive financing for Biohaven tied to pipeline development, while SK Bio gains another late-stage asset with potential to commercialize in the United States. For the epilepsy market, the deal reflects continued capital reallocation toward Kv7 channel modulation and the strategy of securing region-specific commercialization rights ahead of pivotal outcomes.